Strong 84.5% Response Rate for LivaNova's Polysync in OSPREY Study
LIVN sits 97% above its 52-week low of $41.015 on light trading volume (0.3× avg).
Summary
LivaNova announced strong results from its OSPREY study for Polysync Programming, demonstrating an 84.5% cumulative response rate for obstructive sleep apnea. Crucially, the study reported no serious adverse events. This positive clinical data follows the company's robust Q1 earnings and raised guidance reported in May. The high efficacy and safety profile are material for a medical device in a significant market, potentially driving future growth and regulatory progress.
At the time of this announcement, LIVN was trading at $80.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $41.02 to $80.96. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.